<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755519</url>
  </required_header>
  <id_info>
    <org_study_id>ODPA 2016</org_study_id>
    <nct_id>NCT02755519</nct_id>
  </id_info>
  <brief_title>Optimizing Diagnosis Of Primary Aldosteronism</brief_title>
  <acronym>ODPA</acronym>
  <official_title>Case Detection and Confirmation, Subtype Classification of Patients With Primary Aldosteronism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To optimize the confirmatory tests for primary aldosteronism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators aim to optimize the three confirmatory tests: salt loading,
      captopril challenge and fludrocortisone suppression, and to confirm a better choice of
      confirming testing for single or combined diagnosis of primary aldosteronism. Additionally,
      the investigators plan to collect blood and tissue samples of PA patients for genetic
      testing, and to proceed a long-term follow-up for further investigating the mechanism
      underlying PA and evaluating the cardio-cerebrovascular complications risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the receiver operating characteristic curve (AUC) for Salt loading test</measure>
    <time_frame>1 week</time_frame>
    <description>Salt loading test will be performed and compared to golden standard such as adrenal venous sampling (AVS) and biopsy results. The area under the curve (AUC) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for captopril challenge test</measure>
    <time_frame>1 week</time_frame>
    <description>Captopril challenge test will be performed and compared to golden standard such as AVS and biopsy results. AUC will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for fludrocortisone suppression test</measure>
    <time_frame>1 week</time_frame>
    <description>Fludrocortisone suppression test will be performed and compared to golden standard such as AVS and biopsy results. AUC will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular diseases in Primary Aldosteronism</measure>
    <time_frame>3 years</time_frame>
    <description>Follow-up for the risk of cardiovascular diseases, chronic kidney disease and stroke</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>Primary Aldosteronism</arm_group_label>
    <description>Those with hypertension, and with or without hypoglycemia;
Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Primary Aldosteronism</arm_group_label>
    <description>Those with Primary Hypertension;
Those with adrenal diseases except for Primary Aldosteronism</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: Who was diagnosed with hypertension according to JNC standard and was considered
        with the possibility of primary aldosteronism.

        Group 2: Control Groups, one group for those without hypertension or with primary
        hypertension; the other group for those with adrenal diseases except for primary
        aldosteronism.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With hypertension;

          -  With adrenal diseases

        Exclusion Criteria:

          -  Pregnant or during lactation period;

          -  Under 18 yr;

          -  BMI ≤ 19 or ≥ 35

          -  With Cancer medical history

          -  Been through cardiovascular diseases in the past 3 months;

          -  Been through malignant arrhythmia, respiratory muscle paralysis or skeletal muscle
             paralysis caused by hypokalemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affilated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F; PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007 Jul;25(7):1433-42.</citation>
    <PMID>17563566</PMID>
  </reference>
  <reference>
    <citation>Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser M. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab. 2014 Aug;99(8):2745-53. doi: 10.1210/jc.2014-1153. Epub 2014 Apr 24.</citation>
    <PMID>24762111</PMID>
  </reference>
  <reference>
    <citation>Li Y, Liu Y, Li J, Wang X, Yu Y. Sodium Infusion Test for Diagnosis of Primary Aldosteronism in Chinese Population. J Clin Endocrinol Metab. 2016 Jan;101(1):89-95. doi: 10.1210/jc.2015-2840. Epub 2015 Nov 13.</citation>
    <PMID>26565948</PMID>
  </reference>
  <reference>
    <citation>Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, Okuno H, Shimatsu A, Suzuki T, Naruse M. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2012 May;97(5):1688-94. doi: 10.1210/jc.2011-2504. Epub 2012 Mar 14.</citation>
    <PMID>22419718</PMID>
  </reference>
  <reference>
    <citation>Schirpenbach C, Seiler L, Maser-Gluth C, Rüdiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol. 2006 Jun;154(6):865-73.</citation>
    <PMID>16728547</PMID>
  </reference>
  <reference>
    <citation>Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001 Jun;37(6):1440-3.</citation>
    <PMID>11408392</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>primary aldosteronism</keyword>
  <keyword>confirmatory test</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

